CNM-Au8 as a Novel Therapeutic Category in MS: Robert Glanzman, MD
The chief medical officer at Clene Nanomedicine discussed the recently presented data on CNM-Au8 from the VISIONARY-MS trial.
“We took those people who had EDSS of 1.5 or less at baseline…and used their baseline values to compare with the entire population over time. When you take the entire population, of course, at baseline, is worse off than the mildly affected population. But, if you look over time…the population as a whole is improving.”
Clene Nanomedicine recently presented 2 posters from the VISIONARY-MS and REPAIR-MS clinical trials of its investigational nanocatalyst agent, CNM-Au8, which suggest that the therapy can improve the levels of NAD+/NADH (nicotinamide adenine dinucleotide) ratio and AT (adenosine triphosphate) levels, as well as scores on a number of MS Functional Composite subscales measuring visual acuity and neurological status.1,2
The VISIONARY-MS interim data showed that the change in the 6-component composite z-score—which included the SDMT, LCLA in both eyes, 9HPT with both dominant and nondominant hands, and T25W—was significantly improved for those with EDSS 2.0 or higher compared to those with EDSS 1.0 or lower (P = .0005).2 The data were presented virtually at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021, February 25-27, by Robert Glanzman, MD, FAAN, chief medical officer, Clene Nanomedicine.
To find out more about the data and what they imply for the clinical community as CNM-Au8 progresses in its clinical development, NeurologyLive caught up with Glanzman in an interview. He offered his insight into the data and his excitement about the novel therapeutic category this agent represents.
For more coverage of ACTRIMS Forum 2021, click here.
